Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

Epileptiform Activity During REM Sleep

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Imaging
Biomarker Measured
Cell signaling
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Recent clinical data showed that patients with Alzheimer Disease (AD) might present epilepsy at early stages of the disease (Cretin et al., 2016, Vossel et al., 2016). In mice models of Alzheimer disease, preclinical researchers observed an increase of epileptic events during Rapid Eye Movement (REM) sleep, which is very unusual. This study aims at testing if patients with AD present an exacerbation of epileptic events during REM sleep, which could constitute an early biomarker of the disease. Investigators will evaluate the incidence of epilepsy during each sleep stage in 40 patients with early or moderate forms of AD and in 40 healthy subjects. Investigators will also look for a link between epilepsy during sleep in AD participants and memory performances, brain damage (by using MRI scans) and in the case of patients, the phenotype of the Apolipoprotein E(ApoE) gene.

Target Population/ Population Being Studied

Patients with AD

Length of Current Trial
2 days
Number of Trial Participants

80

Estimated Trial Completion
April 2012
What is Required from Patients

Overnight sleep study, blood draw, mild discomfort

What is Required from the Health System

overnight sleep clinic, technicians, MRI, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

University Hospital, Toulouse; Centre de Recherches sur la Cognition Animale (CRCA – UMR5169 CNRS/UPS);Centre de Recherche Cerveau & Cognition (CerCo – UMR5549 CNRS/UPS); Toulouse NeuroImaging Center (ToNIC – UMR 1214 Inserm/UPS); Fondation Plan Alzheimer; IHNPS/FHU HoPeS